2 news items
Oncocyte Appoints Andrea James as Chief Financial Officer
AXON
OCX
17 Jun 24
monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI
Axon reports Q1 2024 revenue of $461 million, up 34% year over year, raises outlook
AXON
6 May 24
referring to these non-GAAP financial measures in assessing its performance, and when planning and forecasting our future periods. A reconciliation
- Prev
- 1
- Next